Immunic, Inc. (NASDAQ:IMUX) Stock Rated “Buy” by Wall Street Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned a consensus recommendation of “Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have assigned a buy recommendation and four have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $35.43.

Several research firms have recently weighed in on IMUX. Cantor Fitzgerald began coverage on Immunic in a report on Friday, October 23rd. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Immunic in a research note on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Zacks Research raised shares of Immunic from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Finally, Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday, October 10th.

Immunic Stock Up 2.7%

Shares of Immunic stock opened at $7.96 on Tuesday. The stock’s fifty day simple moving average is $9.22 and its 200 day simple moving average is $11.50. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43.

Immunic (NASDAQ:IMUX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. As a group, research analysts anticipate that Immunic will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Institutional investors have recently added to or reduced their stakes in the stock. Avidity Partners Management LP increased its holdings in Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after purchasing an additional 2,000,000 shares in the last quarter. Aberdeen Group plc raised its stake in shares of Immunic by 32.3% in the 3rd quarter. Aberdeen Group plc now owns 1,090,427 shares of the company’s stock valued at $10,141,000 after purchasing an additional 266,034 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Immunic in the 1st quarter valued at about $1,020,000. Braidwell LP bought a new stake in shares of Immunic in the second quarter valued at about $9,914,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Immunic in the first quarter valued at about $187,000. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies.

Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.